Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesEffects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease
Scandinavian Journal of Rheumatology , 09/28/09
Frostegard AG et al. – Decreased ANXA5 binding to endothelium, mediated by aPL, is a novel mechanism of atherothrombosis that can be countered by IVIg in vitro. IVIg per se could, to a lesser degree, cause decreased ANXA5 binding in NHS, which raises the possibility that some antibodies in IVIg can be involved in a side-effect reported in IVIg treatment, namely atherothrombosis and CVD. Increasing ANXA5 binding, either by addition of ANXA5 or by use of neutralizing antibodies in IVIg, represents a possible therapeutic strategy .
Methods- ANXA5 binding to human umbilical venous endothelial cells (HUVECs) determined by flow cytometry
- Cells cultured in serum from APS patients with high aPL titre (aPL-S)
- Binding of ANXA5 to HUVECs reduced
- Monoclonal immunoglobulin (Ig)G aPL against cardiolipin (mAb-CL) dose-dependently reduced ANXA5 binding to endothelium
- Preincubation of IV Ig at therapeutically relevant doses with aPL-S and mAb-aCL restored ANXA5 binding to comparable levels when NHS used
- IVIg had the capacity to reduce ANXA5 binding to endothelium when added to NHS
Today in Vascular Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Ageing and cardiovascular responses to head-up tilt in healthy subjects
Atherosclerosis, 12/04/09
Liquid versus foam sclerotherapy
Phlebology, 12/04/09
Foam sclerotherapy: cardiac and cerebral monitoring
Phlebology, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor